The Canadian Association of Interventional Cardiology and the Canadian Cardiovascular Society joint statement on drug-eluting stents.
Recent reports of late stent thrombosis events following deployment of drug-eluting stents (DES) have raised concerns about their safety and role in the management of coronary artery disease. The Canadian Association of Interventional Cardiology and the Canadian Cardiovascular Society have carefully examined the available evidence, including the data presented at the recent Food and Drug Administration Circulatory System Devices Advisory Panel meeting. The purpose of the present statement is to summarize the available evidence relating to DES thrombosis and to provide practical recommendations regarding DES use and antiplatelet therapy.
Love
Machael P
MP
Division of Cardiology, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia. michael.love@cdha.nshealth.ca
Schampaert
Erick
E
Cohen
Eric A
EA
Webb
John G
JG
Anderson
Todd J
TJ
Labinaz
Marino
M
Tanguay
Jean-François
JF
Dzavík
Vladimír
V
D004334:Drug Administration Schedule; D006083:Graft Occlusion, Vascular / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D018579:Patient Selection; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D012307:Risk Factors; D015607:Stents / Q000009:adverse effects
D010975:Platelet Aggregation Inhibitors